Streetbeat News

Products Services

ADIL

Adial Therapeutics has expanded its intellectual property protection with a new patent covering the combination of its proprietary genetic diagnostic to identify patients with specific genotypes.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:00 pm

JNJ

The European Commission (EC) has approved Carvykti for the treatment of relapsed or refractory multiple myeloma, according to Bloomberg. This approval marks a significant milestone for patients with this condition, offering a new therapeutic option. Johnson & Johnson (JNJ), likely involved in the development or distribution of Carvykti, may see a positive impact from this news.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:57 am

DGX

Quest Diagnostics has expanded its suite of services with the addition of p-tau217 blood biomarker testing, aimed at assessing risk and aiding in the diagnosis of Alzheimer's Disease. This development represents an advancement in the early detection and management of Alzheimer's, leveraging blood-based biomarkers for a more accessible and potentially earlier diagnosis.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:56 am

CTSH

MSFT

Cognizant (NASDAQ:CTSH) and Microsoft Corp. (NASDAQ:MSFT) have expanded their partnership to drive the adoption of Microsoft's generative AI and Copilots across enterprises, aiming to transform business operations and accelerate innovation. This collaboration is expected to significantly contribute to the U.S. and India's GDP through AI adoption. Cognizant has also invested in 25,000 Microsoft 365 Copilot seats and plans to deploy these technologies to a million users within their global clients across various industries.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:52 am

LI

Li Auto shares are trading lower following reports of the company implementing price cuts on its vehicles.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:49 am

MLEC

Moolec Science shares surged following the announcement of USDA approval for its plant-grown animal proteins, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:42 am

LXEO

Lexeo Therapeutics has entered into an in-license agreement with Cornell University to accelerate the development of LX2006 for treating Friedreich Ataxia Cardiomyopathy. This agreement grants Lexeo certain rights, including access to current and future data from an ongoing Phase 1A trial of AAVrh.10hFXN aimed at treating FA cardiomyopathy.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:32 am

KURA

Kura Oncology's drug, Ziftomenib, received FDA Breakthrough Therapy Designation for treating relapsed/refractory NPM1-mutant Acute Myeloid Leukemia, potentially accelerating its development and review process.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:32 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) is facing a sell-off, with its stock set to open at 15-month lows due to recent price cuts across its U.S. and international electric-vehicle lineups, excluding the refreshed Model 3 and Cybertruck. The price reduction strategy, including a significant cut in its full self-driving software price, is seen as margin-eroding ahead of its Q1 earnings report. Analysts, including Future Fund's Gary Black, anticipate these moves could lead to a $2.7 billion annual revenue loss and a 60 cents per share earnings reduction, prompting a negative outlook and potential further price target adjustments by Wall Street.

Portfolio Pulse from Shanthi Rexaline

April 22, 2024 | 11:24 am

CNTA

The FDA has approved Centessa Pharmaceuticals' application to begin a Phase 1 clinical trial of ORX750, a new drug aimed at treating narcolepsy. This marks a significant step for Centessa in advancing its pipeline and potentially addressing a critical need in narcolepsy treatment.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:09 am